Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-[4-(trideuteriomethoxy)phenyl]-5H-pyrazolo[4,3-c]quinolin-3-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 2-(4-hydroxyphenyl)-7-methoxy-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(4-hydroxyphenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-[4-(trideuteriomethoxy)phenyl]-5H-pyrazolo[4,3-c]quinolin-3-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 2-(4-hydroxyphenyl)-7-methoxy-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(4-hydroxyphenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Positive allosteric modulation of GABA-A receptor alpha6beta3gamma2 (unknown origin) expressed in Xenopus laevis oocytes assessed as potentiation of EC3 GABA induced currents at 30 uM at -60 mV holding potential by electrophysiological method relative to GABA
Neurotoxicity in Swiss Webster mouse assessed as induction of motor impairment at 40 mg/kg administered via oral gavage measured after 10 to 60 mins by rotarod method